Table 1.
Baseline demographics and characteristics of Asian patients in long‐term CV outcomes trials of atorvastatin stratified by treatmenta
| ATV 10 mg | ATV 80 mg | Placebo | |
|---|---|---|---|
| No. of Asian patients | 238 | 106 | 186 |
| Age (years) | 58.3 (8.1) | 59.1 (9.7) | 58.2 (9.4) |
| Age ≥65 years, n (%) | 57 (23.9) | 35 (33.0) | 46 (24.7) |
| Age ≥70 years, n (%) | 13 (5.5)b | 15 (14.2)b | 18 (9.7) |
| Male gender, n (%) | 188 (79.0) | 87 (82.1) | 142 (76.3) |
| Smoking status, n (%) | |||
| Current smoker | 33 (13.9) | 7 (6.6)c | 28 (15.1) |
| Non/ex‐smoker | 205 (86.1) | 99 (93.4)c | 158 (84.9) |
| BMI (kg/m2) | 26.7 (3.5) | 25.9 (2.9)c | 27.2 (4.1) |
| BP (mm Hg) | |||
| SBP | 139.2 (19.5)b , c | 128.7 (17.9)b , c | 143.3 (21.6) |
| DBP | 82.9 (10.6)b , c | 79.7 (10.7)b , c | 86.0 (10.6) |
| Lipids (mg/dL) | |||
| LDL‐C | 109.0 (30.3)c | 103.6 (26.9)c | 121.0 (26.5) |
| HDL‐C | 48.6 (11.0) | 47.1 (10.5) | 49.5 (12.7) |
| Total cholesterol | 187.5 (35.5)b , c | 179.2 (29.8)b , c | 201.2 (29.5) |
| Triglycerides | 148.5 (77.5) | 144.8 (61.3) | 155.2 (72.3) |
| BUN (mg/dL) | 15.2 (4.5) | 16.0 (5.4) | 14.8 (4.1) |
| Creatinine (mg/dL) | 1.12 (0.19)b | 1.18 (0.21)b | 1.14 (0.22) |
| HbA1c (%)d | 7.7 (1.5)b | 6.5 (1.4)b , c | 7.8 (1.5) |
Values are mean (SD) or n (%). To convert mg/dL to mmol/L for cholesterol, divide by 38.67; for triglycerides, divide by 88.57; for BUN, multiply by 0.357. To convert mg/dL to μmol/L for creatinine, multiply by 88.4. Trials and endpoints included: ASCOT‐LLA, Anglo‐Scandinavian Cardiac Outcomes Trial–Lipid‐Lowering Arm (primary endpoint: nonfatal myocardial infarction [MI] and fatal coronary heart disease [CHD]); ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non‐Insulin‐Dependent Diabetes Mellitus (primary endpoint: time to the first occurrence of cardiovascular death, nonfatal or silent MI, nonfatal stroke, recanalization, coronary artery bypass grafting, resuscitated cardiac arrest, or worsening or unstable angina requiring hospitalization); CARDS, Collaborative Atorvastatin Diabetes Study (primary endpoint: time to first occurrence of acute CHD event, coronary revascularization, or stroke); IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering study (primary endpoint: composite of major coronary event, defined as coronary death, hospitalization for nonfatal acute MI, or resuscitated cardiac arrest); SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels study (primary end point: a first nonfatal or fatal stroke); TNT, Treating to New Targets study (primary endpoint: the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal nonprocedure‐related MI, resuscitation after cardiac arrest, or fatal or nonfatal stroke). ATV, atorvastatin; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; SD, standard deviation.
Atorvastatin and placebo treatment groups are shown; for simvastatin 20–40 mg in IDEAL, see Table S1.
P < 0.05 versus other atorvastatin dose.
P < 0.05 versus placebo.
Approximately 25% of all patients in TNT had values for HbA1c; for the Asian participants in TNT, this rate was about 40%.